NasdaqGS - Nasdaq Real Time Price USD

Akero Therapeutics, Inc. (AKRO)

42.79

+0.77

+(1.83%)

At close: May 7 at 4:00:00 PM EDT

43.31

+0.52

+(1.22%)

Pre-Market: 8:31:17 AM EDT

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Compan

GlobeNewswire 16 hours ago

AKRO
+1.83%
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands. Details for the presentations are as fol

GlobeNewswire 8 days ago

AKRO
+1.83%
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Here is how Agilon Health (AGL) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Zacks 2 months ago

AKRO
+1.83%

AGL
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]

Insider Monkey 2 months ago

AKRO
+1.83%
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 -- SOUTH SAN FR

GlobeNewswire 2 months ago

AKRO
+1.83%
Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […]

Insider Monkey 2 months ago

AKRO
+1.83%

^GSPC
Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared Holz, […]

Insider Monkey 2 months ago

AKRO
+1.83%
Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing healthcare stocks so far in 2025. The Healthcare Sector and its Dynamics in the Stock Market Despite the […]

Insider Monkey 2 months ago

AKRO
+1.83%
Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Anyone who’s looked at the market in the last couple of weeks will know that there were some events […]

Insider Monkey 3 months ago

AKRO
+1.83%
This Stock Just Doubled in 1 Day -- Is It Still a Buy?

Unsurprisingly, Akero owes this incredible one-day gain to data from a midstage clinical trial. Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a dangerous buildup of fat in the liver, leading to fibrosis (scarring of the liver) or, in some cases, a severe version known as cirrhosis.

Motley Fool 3 months ago

AKRO
+1.83%
Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best booming stocks to invest in now. The U.S. stock market closed on a downbeat on Friday, January 31, as investors grappled […]

Insider Monkey 3 months ago

AKRO
+1.83%

COMP
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to p

GlobeNewswire 3 months ago

AKRO
+1.83%
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks 3 months ago

BIIB

SAGE

AKRO
+1.83%
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks 3 months ago

SAGE

BIIB

CYTK
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.

Zacks 3 months ago

AKRO
+1.83%

NVO
BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 3 months ago

BIOA

AKRO
+1.83%

VNDA
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purcha

GlobeNewswire 3 months ago

AKRO
+1.83%
Akero’s cirrhosis treatment shows promise in Phase IIb study

In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.

Clinical Trials Arena 3 months ago

AKRO
+1.83%
Why Akero Therapeutics Inc. (AKRO) Surged on Monday

We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note, with the Dow Jones the sole gainer, […]

Insider Monkey 3 months ago

AKRO
+1.83%

^GSPC
Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.

Investor's Business Daily 3 months ago

AKRO
+1.83%

ETNB

Performance Overview

Return	AKRO	S&P 500 (^GSPC)
YTD	+53.81%	-4.26%
1-Year	+94.32%	+8.55%
3-Year	+283.42%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?

Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025

Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High

This Stock Just Doubled in 1 Day -- Is It Still a Buy?

Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero’s cirrhosis treatment shows promise in Phase IIb study

Why Akero Therapeutics Inc. (AKRO) Surged on Monday

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Performance Overview